

Elias A Mossialos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1756108/publications.pdf>

Version: 2024-02-01

277
papers

9,696
citations

47006

47
h-index

56724

83
g-index

291
all docs

291
docs citations

291
times ranked

11708
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of the NHS England evidence-based interventions programme: a difference-in-difference analysis. <i>BMJ Quality and Safety</i> , 2023, 32, 90-99.	3.7	8
2	Study design, result posting, and publication of late-stage cardiovascular trials. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 277-288.	4.0	5
3	COVID-19 vaccine mandate for healthcare workers in the United States: a social justice policy. <i>Expert Review of Vaccines</i> , 2022, 21, 37-45.	4.4	22
4	Digital Health Paradox: International Policy Perspectives to Address Increased Health Inequalities for People Living With Disabilities. <i>Journal of Medical Internet Research</i> , 2022, 24, e33819.	4.3	49
5	A clinical and cost-effectiveness analysis of the HeartMate 3 left ventricular assist device for transplant-ineligible patients: A United Kingdom perspective. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 174-186.	0.6	13
6	Drawing light from the pandemic: Rethinking strategies for health policy and beyond. <i>Health Policy</i> , 2022, 126, 1-6.	3.0	24
7	What has the 2020 Tokyo Olympic and Paralympic Games taught global health on sporting mass gatherings under COVID-19 pandemic?. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2022, 41, 101001.	1.4	2
8	Delayed medical care due to transportation barriers among adults with atherosclerotic cardiovascular disease. <i>American Heart Journal</i> , 2022, 245, 60-69.	2.7	4
9	European Society of Cardiology: cardiovascular disease statistics 2021. <i>European Heart Journal</i> , 2022, 43, 716-799.	2.2	343
10	Social determinants of health and obesity: Findings from a national study of US adults. <i>Obesity</i> , 2022, 30, 491-502.	3.0	34
11	Promoting innovation while controlling cost: The UK's approach to health technology assessment. <i>Health Policy</i> , 2022, 126, 224-233.	3.0	7
12	DISCRETE CHOICE EXPERIMENT TO INVESTIGATE PREFERENCES FOR INCENTIVES TO PROMOTE ANTIMICROBIAL RESEARCH & DEVELOPMENT. <i>Journal of Global Antimicrobial Resistance</i> , 2022, , .	2.2	0
13	Are we heading for a two tier healthcare system in the UK?. <i>BMJ, The</i> , 2022, 376, o618.	6.0	5
14	Social Determinants of Disparities in Mortality Outcomes in Congenital Heart Disease: A Systematic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 829902.	2.4	17
15	Clinical and Economic Profile of Homeless Young Adults with Stroke in the United States, 2002 â€“ 2017. <i>Current Problems in Cardiology</i> , 2022, , 101190.	2.4	2
16	Health impacts of the Russian invasion in Ukraine: need for global health action. <i>Lancet, The</i> , 2022, 399, 1450-1452.	13.7	45
17	Mental health and conspirasism in health care professionals during the spring 2020 COVID-19 lockdown in Greece. <i>Acta Neuropsychiatrica</i> , 2022, 34, 132-147.	2.1	5
18	Effectiveness of government policies in response to the first COVID-19 outbreak. <i>PLOS Global Public Health</i> , 2022, 2, e0000242.	1.6	25

#	ARTICLE	IF	CITATIONS
19	European Society of Cardiology: cardiovascular disease statistics 2021: Executive Summary. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 377-382.	4.0	29
20	Effective post-pandemic governance must focus on shared challenges. Lancet, The, 2022, 399, 1999-2001.	13.7	9
21	United Kingdom: Health System Review.. Health Systems in Transition, 2022, 24, 1-194.	5.2	1
22	Patient-reported disruptions to cancer care in the U.S. during the COVID-19 pandemic: A national cross-sectional study.. Journal of Clinical Oncology, 2022, 40, 10561-10561.	1.6	0
23	Subjective Financial Hardship due to Medical Bills Among Patients With Heart Failure in the United States: The 2014-2018 Medical Expenditure Panel Survey. Journal of Cardiac Failure, 2022, 28, 1424-1433.	1.7	8
24	Challenges of balancing international health and travel in a pandemic: Lessons from the French Caribbean during COVID-19 passports. The Lancet Regional Health Americas, 2022, 13, 100327.	2.6	0
25	An Initial Analysis of the Effects of a Long-Term Care Insurance on Equity and Efficiency: A Case Study of Qingdao City in China. Research on Aging, 2021, 43, 156-165.	1.8	9
26	The "Netflix plus model": can subscription financing improve access to medicines in low- and middle-income countries?. Health Economics, Policy and Law, 2021, 16, 113-123.	1.8	7
27	For-Profit Hospitals Have Thrived Because of Generous Public Reimbursement Schemes, Not Greater Efficiency: A Multi-Country Case Study. International Journal of Health Services, 2021, 51, 67-89.	2.5	16
28	Accountability and transparency are vital in a pandemic response. Journal of General and Family Medicine, 2021, 22, 113-114.	0.8	2
29	Physician Density by Specialty Type in Urban and Rural Counties in the US, 2010 to 2017. JAMA Network Open, 2021, 4, e2033994.	5.9	36
30	The UK Health and Care Bill: failure to address fundamental issues of coverage and funding. Lancet, The, 2021, 397, 1259.	13.7	0
31	Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval. JAMA Internal Medicine, 2021, 181, 490.	5.1	32
32	Securing a sustainable and fit-for-purpose UK health and care workforce. Lancet, The, 2021, 397, 1992-2011.	13.7	64
33	COVID-19 vaccine challenges: What have we learned so far and what remains to be done?. Health Policy, 2021, 125, 553-567.	3.0	199
34	What is the right level of spending needed for health and care in the UK?. Lancet, The, 2021, 397, 2012-2022.	13.7	15
35	End-of-Life Planning Depends on Socio-Economic and Racial Background: Evidence from the US Health and Retirement Study (HRS). Journal of Pain and Symptom Management, 2021, 62, 1198-1206.	1.2	7
36	LSE "Lancet Commission on the future of the NHS: re-laying the foundations for an equitable and efficient health and care service after COVID-19. Lancet, The, 2021, 397, 1915-1978.	13.7	49

#	ARTICLE	IF	CITATIONS
37	A County-Level Analysis of Socioeconomic and Clinical Predictors of COVID-19 Incidence and Case-Fatality Rates in Georgia, March–September 2020. <i>Public Health Reports</i> , 2021, 136, 626-635.	2.5	5
38	Health information technology and digital innovation for national learning health and care systems. <i>The Lancet Digital Health</i> , 2021, 3, e383-e396.	12.3	107
39	The impact of primary health care and specialist physician supply on amenable mortality in Mexico (2000–2015): Panel data analysis using system-Generalized Method of Moments. <i>Social Science and Medicine</i> , 2021, 278, 113937.	3.8	8
40	Divergent vaccination policies could fuel mistrust and hesitancy. <i>Lancet</i> , The, 2021, 397, 2333.	13.7	15
41	Financial Risk Protection and Unmet Healthcare Need in Russia. <i>International Journal of Health Policy and Management</i> , 2021, , .	0.9	5
42	“Erring on the side of rare events”? A behavioural explanation for COVID-19 vaccine regulatory misalignment. <i>Journal of Global Health</i> , 2021, 11, 03080.	2.7	2
43	Clinical negligence cases in the English NHS: uncertainty in evidence as a driver of settlement costs and societal outcomes. <i>Health Economics, Policy and Law</i> , 2021, , 1-16.	1.8	0
44	Can the US COVID-19 Response Advance Equity in Cardiovascular Health?. <i>European Heart Journal</i> , 2021, 42, 3897-3899.	2.2	1
45	The Coverage in England of US-Approved Cancer Drugs—Reply. <i>JAMA Internal Medicine</i> , 2021, 181, 1263.	5.1	0
46	The Relationship Between the COVID-19 Pandemic and Vaccine Hesitancy: A Scoping Review of Literature Until August 2021. <i>Frontiers in Public Health</i> , 2021, 9, 747787.	2.7	62
47	Financial protection in health among the middle-aged and elderly: Evidence from the Greek economic recession. <i>Health Policy</i> , 2021, 125, 1256-1266.	3.0	4
48	Economic Aspects of Delivering Primary Care Services: An Evidence Synthesis to Inform Policy and Research Priorities. <i>Milbank Quarterly</i> , 2021, 99, 974-1023.	4.4	5
49	A new strategy for health and sustainable development in the light of the COVID-19 pandemic. <i>Lancet</i> , The, 2021, 398, 1029-1031.	13.7	16
50	The cost of prejudice for poorer people: understanding experiences of discrimination in cardiac arrest care. <i>European Heart Journal</i> , 2021, 42, 870-872.	2.2	2
51	Navigating the role of the EU Health Emergency Preparedness and Response Authority (HERA) in Europe and beyond. <i>Lancet Regional Health - Europe</i> , The, 2021, 9, 100203.	5.6	15
52	Evaluation of progress toward universal health coverage in Myanmar: A national and subnational analysis. <i>PLoS Medicine</i> , 2021, 18, e1003811.	8.4	8
53	The EU Response to COVID-19: From Reactive Policies to Strategic Decision-Making. <i>Journal of Common Market Studies</i> , 2021, 59, 56-68.	2.1	20
54	Global consumption of prescription opioid analgesics between 2009-2019: a country-level observational study. <i>EClinicalMedicine</i> , 2021, 42, 101198.	7.1	40

#	ARTICLE	IF	CITATIONS
55	European Society of Cardiology: Cardiovascular Disease Statistics 2019. <i>European Heart Journal</i> , 2020, 41, 12-85.	2.2	690
56	Association between provincial income levels and drug prices in China over the period 2010–2017. <i>Social Science and Medicine</i> , 2020, 263, 113247.	3.8	1
57	Lives cut short: socioeconomic inequities, homelessness, and cardiovascular disease. <i>European Heart Journal</i> , 2020, 41, 4021-4023.	2.2	5
58	Cost-effectiveness of Cardiovascular, Obesity, and Diabetes Mellitus Drugs: Comparative Analysis of the United States and England. <i>Journal of the American Heart Association</i> , 2020, 9, e018281.	3.7	2
59	The UK needs a sustainable strategy for COVID-19. <i>Lancet</i> , 2020, 396, 1800-1801.	13.7	23
60	Ensuring access and affordability through COVID-19 vaccine research and development investments: A proposal for the options market for vaccines. <i>Vaccine</i> , 2020, 38, 6075-6077.	3.8	17
61	Time to strengthen capacity in infectious disease control at the European level. <i>International Journal of Infectious Diseases</i> , 2020, 99, 263-265.	3.3	6
62	Inequality in healthcare use among older people in Colombia. <i>International Journal for Equity in Health</i> , 2020, 19, 168.	3.5	27
63	Elective cardiovascular care in the era of the COVID-19 pandemic: managing tragic choices. <i>BMJ Open Quality</i> , 2020, 9, e001069.	1.1	0
64	Resurgence of covid-19 in Japan. <i>BMJ</i> , 2020, 370, m3221.	6.0	67
65	Cost-effectiveness of cancer drugs: Comparative analysis of the United States and England. <i>EClinicalMedicine</i> , 2020, 29-30, 100625.	7.1	21
66	The health and economic burden of antimicrobial resistance. , 2020, , 23-44.		2
67	Tackling antimicrobial resistance in the community. , 2020, , 45-70.		2
68	The role of vaccines in combating antimicrobial resistance. , 2020, , 181-206.		2
69	Why private health insurance?. , 2020, , 1-40.		4
70	Private finance publicly subsidized: the case of Australian health insurance. , 2020, , 41-64.		3
71	Private health insurance in Brazil, Egypt and India. , 2020, , 65-98.		1
72	Private health insurance in Canada. , 2020, , 99-141.		2

#	ARTICLE	IF	CITATIONS
73	Regulating private health insurance:France's attempt at getting it all. , 2020, , 142-179.		0
74	Statutory and private health insurance in Germany and Chile: two stories of coexistence and conflict. , 2020, , 180-220.		0
75	Uncovering the complex role of private health insurance in Ireland. , 2020, , 221-263.		4
76	Integrating public and private insurance in the Israeli health system: an attempt to reconcile conflicting values. , 2020, , 264-303.		1
77	Private health insurance in Japan, Republic of Korea and Taiwan, China. , 2020, , 304-324.		0
78	The role of private health insurance in financing health care in Kenya. , 2020, , 325-348.		0
79	Private health insurance in the Netherlands. , 2020, , 349-376.		0
80	The challenges of pursuing private health insurance in low- and middle-income countries: lessons from South Africa. , 2020, , 377-413.		2
81	Undermining risk pooling by individualizing benefits: the use of medical savings accounts in South Africa. , 2020, , 414-445.		2
82	Consumer-driven health insurance in Switzerland, where politics is governed by federalism and direct democracy. , 2020, , 446-493.		1
83	Regression to the increasingly mean? Private health insurance in the United States of America. , 2020, , 494-524.		4
84	Health savings accounts in the United States of America. , 2020, , 525-551.		0
85	Tackling antimicrobial resistance in the hospital sector. , 2020, , 71-98.		0
86	Tackling antimicrobial resistance in the food and livestock sector. , 2020, , 99-124.		1
87	Fostering R&D of novel antibiotics and other technologies to prevent and treat infection. , 2020, , 125-154.		0
88	Ensuring innovation for diagnostics for bacterial infection to combat antimicrobial resistance. , 2020, , 155-180.		0
89	Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US. Social Science and Medicine, 2020, 258, 113042.	3.8	28
90	Quality of primary health care in China: challenges and recommendations. Lancet, The, 2020, 395, 1802-1812.	13.7	391

#	ARTICLE	IF	CITATIONS
91	The relationship between off-hours admissions for primary percutaneous coronary intervention, door-to-balloon time and mortality for patients with ST-elevation myocardial infarction in England: a registry-based prospective national cohort study. <i>BMJ Quality and Safety</i> , 2020, 29, 541-549.	3.7	13
92	Developing a sustainable exit strategy for COVID-19: health, economic and public policy implications. <i>Journal of the Royal Society of Medicine</i> , 2020, 113, 176-178.	2.0	35
93	12 Lessons learned from the management of the coronavirus pandemic. <i>Health Policy</i> , 2020, 124, 577-580.	3.0	137
94	The impact of the COVID-19 pandemic on cancer care. <i>Nature Cancer</i> , 2020, 1, 565-567.	13.2	392
95	Covid-19 exposes weaknesses in European response to outbreaks. <i>BMJ, The</i> , 2020, 368, m1075.	6.0	73
96	Parental migration and self-reported health status of adolescents in China: A cross-sectional study. <i>EClinicalMedicine</i> , 2020, 22, 100371.	7.1	9
97	NICE's evaluations of medicines authorized by EMA with conditional marketing authorization or under exceptional circumstances. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 426-433.	0.5	7
98	Assessment of technical errors and validation processes in economic models submitted by the company for NICE technology appraisals. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 311-316.	0.5	3
99	Improving transparency and performance of private hospitals. <i>BMJ, The</i> , 2020, 368, m577.	6.0	5
100	Rebuilding Sudan's health system: opportunities and challenges. <i>Lancet, The</i> , 2020, 395, 171-173.	13.7	12
101	Incentivising antibiotic research and development: is the UK's subscription payment model part of the solution?. <i>Lancet Infectious Diseases, The</i> , 2020, 20, 162-163.	9.1	5
102	Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs. <i>Value in Health</i> , 2020, 23, 319-327.	0.3	15
103	Rebuilding the broken health contract in Chile. <i>Lancet, The</i> , 2020, 395, 1342.	13.7	22
104	Health system, public health, and economic implications of managing COVID-19 from a cardiovascular perspective. <i>European Heart Journal</i> , 2020, 41, 2516-2518.	2.2	64
105	Patient Choice of Health Care Providers in China: Primary Care Facilities versus Hospitals. <i>Health Systems and Reform</i> , 2020, 6, e1846844.	1.2	23
106	Understanding personal health budgets. <i>BMJ, The</i> , 2020, 368, m324.	6.0	2
107	U.S. Healthcare Insurance Market Concentration from 2001 to 2016: Increased Growth in Direct Written Premiums and Overall Decreased Market Consolidation. <i>Cureus</i> , 2020, 12, e7491.	0.5	3
108	The role of civil society in tackling antimicrobial resistance. , 2020, , 207-240.		0

#	ARTICLE	IF	CITATIONS
109	Does economic recession impact newborn health? Evidence from Greece. <i>Social Science and Medicine</i> , 2019, 237, 112451.	3.8	18
110	A governance framework for development and assessment of national action plans on antimicrobial resistance. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e371-e384.	9.1	62
111	Beyond gross domestic product for New Zealand's wellbeing budget. <i>Lancet Public Health</i> , The, 2019, 4, e320-e321.	10.0	23
112	Self-reported Symptoms of Depression Among Chinese Rural-to-Urban Migrants and Left-Behind Family Members. <i>JAMA Network Open</i> , 2019, 2, e193355.	5.9	16
113	It's not ageing, stupid: why population ageing won't bankrupt health systems. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 5, 195-201.	4.0	16
114	Investing in health R&D: where we are, what limits us, and how to make progress in Africa. <i>BMJ Global Health</i> , 2019, 4, e001047.	4.7	62
115	Time to address the plight of the people of northeastern Syria. <i>Lancet</i> , The, 2019, 393, 1394-1396.	13.7	1
116	Risk factors for death or heart transplantation in single-ventricle physiology (tricuspid atresia). <i>Transplantation</i> , 2019, 38, 739-747.	0.6	12
117	Organ Donation and Drug Intoxication-Related Deaths in the United States. <i>New England Journal of Medicine</i> , 2019, 380, 597-599.	27.0	12
118	Virtual primary care: fragmentation or integration?. <i>The Lancet Digital Health</i> , 2019, 1, e330-e331.	12.3	21
119	Performance of UK National Health Service compared with other high income countries: observational study. <i>BMJ</i> , The, 2019, 367, l6326.	6.0	57
120	The impact of the Greek economic adjustment programme on household health expenditure. <i>Social Science and Medicine</i> , 2019, 222, 274-284.	3.8	13
121	A review of NICE appraisals of pharmaceuticals 2000-2016 found variation in establishing comparative clinical effectiveness. <i>Journal of Clinical Epidemiology</i> , 2019, 105, 50-59.	5.0	25
122	Assessment of Devices, Diagnostics and Digital Technologies: A Review of NICE Medical Technologies Guidance. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 189-211.	2.1	8
123	Malaria and Macronutrient Deficiency as Correlates of Anemia in Young Children: A Systematic Review of Observational Studies. <i>Annals of Global Health</i> , 2018, 80, 458.	2.0	24
124	Implementation of Transcatheter Aortic Valve Replacement in France. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1614-1627.	2.8	68
125	The future of the NHS: no longer the envy of the world?. <i>Lancet</i> , The, 2018, 391, 1001-1003.	13.7	9
126	What are the requirements for developing a successful national registry of auditory implants? A qualitative study. <i>BMJ Open</i> , 2018, 8, e021720.	1.9	18

#	ARTICLE	IF	CITATIONS
127	After Astana: building the economic case for increased investment in primary health care. <i>Lancet, The</i> , 2018, 392, 2147-2152.	13.7	16
128	Prices For Cardiac Implant Devices May Be Up To Six Times Higher In The US Than In Some European Countries. <i>Health Affairs</i> , 2018, 37, 1570-1577.	5.2	23
129	What are the economic barriers of antibiotic R&D and how can we overcome them?. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 889-892.	5.0	37
130	How primary health care can make universal health coverage a reality, ensure healthy lives, and promote wellbeing for all. <i>Lancet, The</i> , 2018, 392, 1372-1374.	13.7	29
131	An ethical appraisal of living-anonymous kidney donation using Adam Smith's Theory of Moral Sentiments. <i>Health Policy</i> , 2018, 122, 1212-1221.	3.0	7
132	Membership In Seguro Popular In Mexico Linked To A Small Reduction In Catastrophic Health Expenditure. <i>Health Affairs</i> , 2018, 37, 1169-1177.	5.2	16
133	Equity of access to maternal health interventions in Brazil and Colombia: a retrospective study. <i>International Journal for Equity in Health</i> , 2018, 17, 43.	3.5	17
134	Brexit and the NHS: Challenges, uncertainties and opportunities. <i>Health Policy</i> , 2017, 121, 477-480.	3.0	15
135	Estimating the incidence and the economic burden of third and fourth-degree obstetric tears in the English NHS: an observational study using propensity score matching. <i>BMJ Open</i> , 2017, 7, e015463.	1.9	15
136	Global health financing towards 2030 and beyond. <i>Health Economics, Policy and Law</i> , 2017, 12, 105-111.	1.8	10
137	Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines. <i>JAMA Oncology</i> , 2017, 3, 382.	7.1	105
138	Effectiveness of UK provider financial incentives on quality of care: a systematic review. <i>British Journal of General Practice</i> , 2017, 67, e800-e815.	1.4	21
139	Protocol for a nationwide survey of primary health care in China: the China PEACE (Patient-centered) Tj ETQq1 1 0.784314 rgBT /Over BMJ Open, 2017, 7, e016195.	1.9	12
140	Systematic review of economic analyses in patient safety: a protocol designed to measure development in the scope and quality of evidence. <i>BMJ Open</i> , 2017, 7, e017089.	1.9	4
141	Crowdfunding our health: Economic risks and benefits. <i>Social Science and Medicine</i> , 2017, 191, 48-56.	3.8	75
142	Overestimating the Benefit of Cancer Drugs's Reply. <i>JAMA Oncology</i> , 2017, 3, 1738.	7.1	1
143	Health policy in times of austerity's A conceptual framework for evaluating effects of policy on efficiency and equity illustrated with examples from Europe since 2008. <i>Health Policy</i> , 2017, 121, 947-954.	3.0	22
144	Does health insurance reduce out-of-pocket expenditure? Heterogeneity among China's middle-aged and elderly. <i>Social Science and Medicine</i> , 2017, 190, 11-19.	3.8	68

#	ARTICLE	IF	CITATIONS
145	The primary health-care system in China. <i>Lancet, The</i> , 2017, 390, 2584-2594.	13.7	609
146	Availability, cost, and prescription patterns of antihypertensive medications in primary health care in China: a nationwide cross-sectional survey. <i>Lancet, The</i> , 2017, 390, 2559-2568.	13.7	103
147	Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps. <i>Journal of Antibiotics</i> , 2017, 70, 1087-1096.	2.0	171
148	Addressing the Challenges in Tonsillectomy Research to Inform Health Care Policy. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 943.	2.2	12
149	Analysis Of End-Of-Life Care, Out-Of-Pocket Spending, And Place Of Death In 16 European Countries And Israel. <i>Health Affairs</i> , 2017, 36, 1201-1210.	5.2	26
150	Accelerated access to new drugs and technologies. <i>BMJ: British Medical Journal</i> , 2017, 359, j5387.	2.3	6
151	Training the next generation of cardiovascular leaders in health policy and economics. <i>European Heart Journal</i> , 2017, 38, 3332-3335.	2.2	2
152	What are the essential features of a successful surgical registry? a systematic review. <i>BMJ Open</i> , 2017, 7, e017373.	1.9	53
153	Financing institutional long-term care for the elderly in China: a policy evaluation of new models. <i>Health Policy and Planning</i> , 2016, 31, 1391-1401.	2.7	66
154	Structural equation model for estimating risk factors in type 2 diabetes mellitus in a Middle Eastern setting: evidence from the STEPS Qatar. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000231.	2.8	11
155	Cancer Drugs Provide Positive Value In Nine Countries, But The United States Lags In Health Gains Per Dollar Spent. <i>Health Affairs</i> , 2016, 35, 813-823.	5.2	24
156	Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts. <i>Health Policy</i> , 2016, 120, 519-534.	3.0	65
157	A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK. <i>Health Policy</i> , 2016, 120, 1104-1114.	3.0	25
158	A critical analysis of the review on antimicrobial resistance report and the infectious disease financing facility. <i>Globalization and Health</i> , 2016, 12, 8.	4.9	90
159	Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline. <i>Social Science and Medicine</i> , 2016, 151, 167-172.	3.8	12
160	A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics. <i>Journal of Antibiotics</i> , 2016, 69, 73-88.	2.0	152
161	Big Data and Health Care: Challenges and Opportunities for Coordinated Policy Development in the EU. <i>Health Systems and Reform</i> , 2015, 1, 285-300.	1.2	41
162	Timely publication and sharing of trial data: opportunities and challenges for comparative effectiveness research in cardiovascular disease. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2015, 1, 58-65.	4.0	6

#	ARTICLE	IF	CITATIONS
163	Antibiotic research and development: business as usual?. Journal of Antimicrobial Chemotherapy, 2015, 70, 1604-7.	3.0	60
164	From "retailers" to health care providers: Transforming the role of community pharmacists in chronic disease management. Health Policy, 2015, 119, 628-639.	3.0	294
165	A national incident reporting and learning system in England and Wales, but at what cost?. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 365-368.	1.4	2
166	Commissioning for equity in the NHS: rhetoric and practice. British Medical Bulletin, 2015, 115, 5-17.	6.9	25
167	Why the drug development pipeline is not delivering better medicines. BMJ, The, 2015, 351, h5542.	6.0	34
168	How Can We Link General Medical and Behavioral Health Care? International Models for Practice and Policy. Psychiatric Services, 2015, 66, 775-777.	2.0	11
169	Strategies for achieving global collective action on antimicrobial resistance. Bulletin of the World Health Organization, 2015, 93, 867-876.	3.3	90
170	The diabetes-obesity-hypertension nexus in Qatar: evidence from the World Health Survey. Population Health Metrics, 2014, 12, 18.	2.7	43
171	Mapping support policies for informal carers across the European Union. Health Policy, 2014, 118, 84-94.	3.0	100
172	Expanding the role of community pharmacists: Policymaking in the absence of policy-relevant evidence?. Health Policy, 2013, 111, 135-148.	3.0	78
173	'Avoidable' mortality: a measure of health system performance in the Czech Republic and Slovakia between 1971 and 2008. Health Policy and Planning, 2013, 28, 508-525.	2.7	7
174	Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model. Globalization and Health, 2013, 9, 58.	4.9	34
175	The Economics of Health Care Delivery. Journal of Pediatric Gastroenterology and Nutrition, 2012, 55, 482-488.	1.8	14
176	Behavioral adjustment to avian flu in Europe during spring 2006: The roles of knowledge and proximity to risk. Social Science and Medicine, 2012, 75, 1362-1371.	3.8	14
177	Balancing economic freedom against social policy principles: EC competition law and national health systems. Health Policy, 2012, 106, 127-137.	3.0	12
178	Equity in health care use among older people in the UK: an analysis of panel data. Applied Economics, 2011, 43, 2229-2239.	2.2	30
179	The Level Of Income Appears To Have No Consistent Bearing On Pharmaceutical Prices Across Countries. Health Affairs, 2011, 30, 1545-1552.	5.2	21
180	Free movement of services in the EU and health care. , 2010, , 461-508.		16

#	ARTICLE	IF	CITATIONS
181	Measuring equity of access to health care. , 2010, , 187-221.		8
182	Health system productivity and efficiency. , 2010, , 222-248.		4
183	Clinical surveillance and patient safety. , 2010, , 286-310.		2
184	Performance measurement in primary care. , 2010, , 371-405.		6
185	Patient-reported outcome measures and performance measurement. , 2010, , 63-86.		5
186	Performance measurement in mental health services. , 2010, , 426-471.		5
187	Public performance reporting on quality information. , 2010, , 537-551.		7
188	The hard politics of soft law: the case of health. , 2010, , 186-230.		18
189	Public health policies. , 2010, , 231-281.		16
190	Health care and the EU: the law and policy patchwork. , 2010, , 84-133.		25
191	EU regulatory agencies and health protection. , 2010, , 134-185.		7
192	Fundamental rights and health care. , 2010, , 282-314.		12
193	The EU pharmaceuticals market: parameters and pathways. , 2010, , 635-682.		5
194	Using composite indicators to measure performance in health care. , 2010, , 339-368.		7
195	Risk adjustment for performance measurement. , 2010, , 251-285.		8
196	Health systems responsiveness: a measure of the acceptability of health-care processes and systems from the user's perspective. , 2010, , 138-186.		16
197	Population health. , 2010, , 27-62.		6
198	The EU legal framework on e-health. , 2010, , 561-588.		12

#	ARTICLE	IF	CITATIONS
199	EU competition law and health policy. , 2010, , 337-378.		11
200	Stoking the antibiotic pipeline. BMJ: British Medical Journal, 2010, 340, c2115-c2115.	2.3	92
201	Can user charges make health care more efficient?. BMJ: British Medical Journal, 2010, 341, c3759-c3759.	2.3	35
202	Primary care and prescription drugs: coverage, cost-sharing, and financial protection in six European countries. Issue Brief (Commonwealth Fund), 2010, 82, 1-14.	0.9	6
203	Optimism and the perceptions of new risks. Journal of Risk Research, 2009, 12, 27-41.	2.6	56
204	Measuring Socioeconomic Differences in Use of Health Care Services by Wealth Versus by Income. American Journal of Public Health, 2009, 99, 1849-1855.	2.7	114
205	When is the Internet a valued communication device for health information in Europe?. Economics of Innovation and New Technology, 2009, 18, 429-445.	3.4	15
206	Attitudes as an Expression of Knowledge and "Political Anchoring": The Case of Nuclear Power in the United Kingdom. Risk Analysis, 2008, 28, 1273-1288.	2.7	50
207	A Conceptual Framework for Community-Based Health Insurance in Low-Income Countries: Social Capital and Economic Development. World Development, 2008, 36, 590-607.	4.9	50
208	Does organ donation legislation affect individuals' willingness to donate their own or their relative's organs? Evidence from European Union survey data. BMC Health Services Research, 2008, 8, 48.	2.2	96
209	Physician revalidation in Europe. Clinical Medicine, 2008, 8, 371-376.	1.9	32
210	Are Feelings of Genetically Modified Food Politically Driven?. Risk Management, 2008, 10, 218-234.	2.3	4
211	Knowledge about Avian Influenza, European Region. Emerging Infectious Diseases, 2008, 14, 1956-1957.	4.3	4
212	EU law and regulation of private health insurance. Health Economics, Policy and Law, 2007, 2, 117-124.	1.8	4
213	The EU's new paediatric medicines legislation: serving children's needs?. Archives of Disease in Childhood, 2007, 92, 808-811.	1.9	34
214	Are perceptions of "risks" and "benefits" of genetically modified food (in)dependent?. Food Quality and Preference, 2007, 18, 173-182.	4.6	55
215	A pricing policy towards the sourcing of cheaper drugs in Cyprus. Health Policy, 2007, 81, 368-375.	3.0	24
216	Regulating Private Health Insurance in the European Union: The Implications of Single Market Legislation and Competition Policy. Journal of European Integration, 2007, 29, 89-107.	2.1	36

#	ARTICLE	IF	CITATIONS
217	Which policies effectively enable smoking cessation? Evidence from the European Union. <i>International Journal of Social Economics</i> , 2006, 33, 77-100.	1.9	5
218	Erring on the Side of Caution? The Heterogeneity of Public Perceptions of Biotechnology Applications in the European Union. <i>Journal of Economic Issues</i> , 2006, 40, 767-777.	0.8	5
219	Pharmaceutical Pricing in Europe: Weighing up the Options. <i>International Social Security Review</i> , 2006, 59, 3-25.	0.8	14
220	Applying the concepts of financial options to stimulate vaccine development. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 641-647.	46.4	14
221	The Public as a Limit to Technology Transfer: The Influence of Knowledge and Beliefs in Attitudes towards Biotechnology in the UK. <i>Journal of Technology Transfer</i> , 2006, 31, 629-645.	4.3	25
222	Bioethical Implications of Globalization: An International Consortium Project of the European Commission. <i>PLoS Medicine</i> , 2006, 3, e43.	8.4	5
223	Regulating medicines in Europe: the European Medicines Agency, marketing authorisation, transparency and pharmacovigilance. <i>Clinical Medicine</i> , 2006, 6, 87-90.	1.9	19
224	Choice of public or private health insurance: learning from the experience of Germany and the Netherlands. <i>Journal of European Social Policy</i> , 2006, 16, 315-327.	2.8	57
225	Is dread of Genetically Modified food associated with the consumers' demand for information?. <i>Applied Economics Letters</i> , 2005, 12, 859-863.	1.8	25
226	The Determinants of Private Medical Insurance Prevalence in England, 1997-2000. <i>Health Services Research</i> , 2005, 40, 195-212.	2.0	64
227	Analysing the Greek health system: a tale of fragmentation and inertia. <i>Health Economics (United Kingdom)</i> , 2005, 14, S3-S6.	1.7	142
228	The contestable nature of health policy analysis. <i>Health Economics (United Kingdom)</i> , 2005, 14, S3-S6.	1.7	11
229	An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom. <i>International Journal of Health Planning and Management</i> , 2005, 20, 291-306.	1.7	53
230	Regulating pharmaceutical markets: improving efficiency and controlling costs in the UK. <i>International Journal of Health Planning and Management</i> , 2005, 20, 375-398.	1.7	25
231	European Health Systems Reforms: Looking Backward to See Forward?. <i>Journal of Health Politics, Policy and Law</i> , 2005, 30, 7-28.	1.9	70
232	The Wanless report and decision-making in public health. <i>Journal of Public Health</i> , 2005, 27, 133-134.	1.8	7
233	Plus Ça Change : Health Sector Reforms in Greece. <i>Journal of Health Politics, Policy and Law</i> , 2005, 30, 143-168.	1.9	51
234	Provider incentives and prescribing behavior in Europe. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2005, 5, 81-93.	1.4	12

#	ARTICLE	IF	CITATIONS
235	â€˜Ambivalentâ€™ individual preferences towards biotechnology in the European Union: products or processes?. <i>Journal of Risk Research</i> , 2005, 8, 341-354.	2.6	19
236	Interest Groups and Health System Reform in Greece. <i>West European Politics</i> , 2005, 28, 420-444.	4.7	34
237	Is there â€˜patient selectionâ€™ in the demand for private maternity care in Greece?. <i>Applied Economics Letters</i> , 2005, 12, 7-12.	1.8	29
238	Constitutional asymmetry and pharmaceutical policy-making in the European Union. <i>Journal of European Public Policy</i> , 2005, 12, 687-709.	4.0	37
239	Equity of access to health care: outlining the foundations for action. <i>Journal of Epidemiology and Community Health</i> , 2004, 58, 655-658.	3.7	318
240	Health technology assessment and its influence on health-care priority setting. <i>International Journal of Technology Assessment in Health Care</i> , 2004, 20, 1-10.	0.5	115
241	Information technology law and health systems in the European Union. <i>International Journal of Technology Assessment in Health Care</i> , 2004, 20, 498-508.	0.5	10
242	EMA and the evaluation of health-related quality of life data in the drug regulatory process. <i>International Journal of Technology Assessment in Health Care</i> , 2004, 20, 311-324.	0.5	9
243	The European Court of Justice and the free movement of patients in the European Union. <i>International Social Security Review</i> , 2003, 56, 3-29.	0.8	4
244	Stimulating pharmaceutical research and development for neglected diseases. <i>Health Policy</i> , 2003, 64, 75-88.	3.0	38
245	Voluntary Health Insurance in the European Union: A Critical Assessment. <i>International Journal of Health Services</i> , 2002, 32, 19-88.	2.5	75
246	Low demand for substitutive voluntary health insurance in Germany. <i>Croatian Medical Journal</i> , 2002, 43, 425-32.	0.7	4
247	Genetic testing and insurance. <i>Journal of the Royal Society of Medicine</i> , 2001, 94, 57-60.	2.0	10
248	Clinical practice and the UK Human Rights Act 1998: protecting individual rights in the interest of the wider community. <i>Clinical Medicine</i> , 2001, 1, 464-469.	1.9	0
249	Has the Portuguese NHS Achieved its Objectives of Equity and Efficiency?. <i>International Social Security Review</i> , 2000, 53, 49-78.	0.8	13
250	Paying for the NHS. <i>BMJ: British Medical Journal</i> , 2000, 320, 197-198.	2.3	9
251	Pharmaceutical Expenditure in Spain: Cost and Control. <i>International Journal of Health Services</i> , 2000, 30, 597-616.	2.5	26
252	Increasing demand while decreasing costs of generic medicines. <i>Lancet, The</i> , 2000, 356, 1784-1785.	13.7	11

#	ARTICLE	IF	CITATIONS
253	Citizens and rationing: analysis of a European survey. Health Policy, 1999, 49, 75-135.	3.0	82
254	Outstanding Regulatory Aspects in the European Pharmaceutical Market. Pharmacoeconomics, 1999, 15, 519-533.	3.3	20
255	International Comparisons of Health Care Expenditures: What We Know and What We Do not Know. Journal of Health Services Research and Policy, 1999, 4, 122-126.	1.7	33
256	The Impact of Managed Care on Clinical Research. Pharmacoeconomics, 1998, 14, 19-25.	3.3	2
257	The Amsterdam Treaty and the Future of European Health Services. Journal of Health Services Research and Policy, 1998, 3, 65-67.	1.7	10
258	Will Managed Care Work in Europe?. Pharmacoeconomics, 1997, 11, 297-305.	3.3	8
259	Citizens' Views on Health Care Systems in the 15 Member States of The European Union. , 1997, 6, 109-116.		126
260	Cost containment and health care reform: a study of the European Union. Health Policy, 1994, 28, 89-132.	3.0	102
261	Measuring financial protection in health. , 0, , 114-137.		12
262	Targets and performance measurement. , 0, , 509-536.		4
263	Attribution and causality in health-care performance measurement. , 0, , 311-338.		0
264	Chronic care. , 0, , 406-425.		0
265	International health system comparisons: from measurement challenge to management tool. , 0, , 641-672.		7
266	Performance measurement and professional improvement. , 0, , 613-640.		3
267	Private health insurance and the internal market. , 0, , 419-460.		15
268	EU law and health professionals. , 0, , 589-634.		3
269	Health systems governance in Europe: the role of European Union law and policy. , 0, , 1-83.		13
270	Enabling patient mobility in the EU: between free movement and coordination. , 0, , 509-560.		17

#	ARTICLE	IF	CITATIONS
271	Public procurement and state aid in national health care systems. , 0, , 379-418.		22
272	EU competition law and public services. , 0, , 315-336.		8
273	Measuring clinical quality and appropriateness. , 0, , 87-113.		1
274	Developing information technology capacity for performance measurement. , 0, , 552-581.		0
275	Incentives for health-care performance improvement. , 0, , 582-612.		4
276	Long-term care quality monitoring using the interRAI common clinical assessment language. , 0, , 472-506.		2
277	The European Health Data Space fails to bridge digital divides. BMJ, The, 0, , e071913.	6.0	16